CNS drug discovery continues to be one of the key growth areas in modern pharmaceutical research, often bringing with it particular challenges in the areas of pharmacokinetics, animal models and translational medicine/clinical predictivity . In addition to more traditional areas of CNS investigation e.g. pain relief and treatment for depression, changes in lifestyle and increasing longevity have opened up new challenges e.g. treatments for Alzheimer’s Disease and Parkinson’s, and for complications associated with obesity. This one day meeting aims to showcase real case histories and emerging technology as well as have experts address the latest developments and future prospects in CNS drug discovery. The meeting will be of interest to all medicinal chemists and other scientists involved in preclinical drug discovery disciplines in the area of CNS disorders.

Programme

09.15 Registration and Coffee

Chair: Ian Churcher (GlaxoSmithKline)

10.00 Ann Hayes (The Ann Hayes Consultancy Ltd)
CNS drug discovery – where are we and what are the prospects for the future?

11.00 Mark Tricklebank (Eli Lilly)
Harnessing preclinical behavioural neuroscience for drug discovery

11.45 Anne Hersey (GlaxoSmithKline)
Use of in-silico methods to aid our understanding of CNS penetration

12.30 Lunch

Chair: Stuart Cameron (Tripos Discovery Research)

13.30 Jeremy Burrows (AstraZeneca, Sweden)
GSK-3 inhibitors for the treatment of Alzheimer’s Disease

14.15 Gavin Whitlock (Pfizer Global R&D)
Discovery of PF-184298, a dual serotonin/noradrenaline reuptake inhibitor

15.00 Tea

15.30 Paul Radcliffe (Organon Laboratories)
Identification and exploration of a novel series of heterocyclic cannabinoid receptor agonists for the treatment of pain

16.15 Gary Tilbrook (CeNeS Limited)
CNS7056B: an ultra-short acting benzodiazepine

17.00 Close of meeting

Registration required:

Yes

Free:

No